John Charles Thomas Sells 642 Shares of Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) EVP John Charles Thomas sold 642 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $302.03, for a total value of $193,903.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Krystal Biotech Stock Up 1.3%

Shares of NASDAQ KRYS traded up $3.95 during trading on Wednesday, reaching $306.63. The company had a trading volume of 144,305 shares, compared to its average volume of 294,027. Krystal Biotech, Inc. has a 12-month low of $123.03 and a 12-month high of $319.48. The business’s 50-day moving average is $275.34 and its 200 day moving average is $259.63. The stock has a market cap of $9.04 billion, a PE ratio of 40.99 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.38. The firm had revenue of $116.36 million during the quarter, compared to analyst estimates of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. On average, analysts anticipate that Krystal Biotech, Inc. will post 7.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on KRYS shares. Citigroup upped their target price on shares of Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Wolfe Research started coverage on shares of Krystal Biotech in a research report on Friday, March 27th. They set a “peer perform” rating for the company. Weiss Ratings upgraded shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, April 9th. Zacks Research cut Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 5th. Finally, The Goldman Sachs Group increased their target price on Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Ten research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $324.11.

Institutional Trading of Krystal Biotech

A number of institutional investors have recently made changes to their positions in KRYS. Bessemer Group Inc. grew its stake in shares of Krystal Biotech by 106.9% in the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock worth $26,000 after acquiring an additional 77 shares during the period. Sound Income Strategies LLC lifted its position in Krystal Biotech by 1,270.0% during the fourth quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock valued at $34,000 after purchasing an additional 127 shares during the period. Western Wealth Management LLC purchased a new stake in Krystal Biotech in the first quarter worth approximately $34,000. Greenline Wealth Management LLC bought a new stake in Krystal Biotech in the 4th quarter worth approximately $34,000. Finally, Danske Bank A S bought a new stake in Krystal Biotech in the 3rd quarter worth approximately $35,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.